Employees: 15
Size YD Bio (YDES) is a United States Health Care company (Medical Specialties) with a market value of $344M, the 2968th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.85 on 18 Nov 2026.
Performance Over six months the shares gained 6.6%, against -15.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 16.9% over the last twelve months (peer median +6.8%); the operating margin is -883.3% (peer median 9.4%).
Valuation It trades at 571.2× enterprise value to sales against a peer median of 4.2× (most expensive of 21).
Short interest Short interest is 0.3% of the free float (30 Oct 2026).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | $596,817 | $510,360 | $0 | $0 |
| Revenue growth | — | +17% | — | — | — |
| Gross profit | n/a | -$42,150 | $50,621 | $0 | $0 |
| EBITDA | n/a | -$5.06M | -$1.36M | -$2.07M | -$2.32M |
| Net income | n/a | -$8.31M | -$1.41M | -$2.55M | $3.79M |
| Free cash flow | n/a | -$8.04M | -$1.30M | -$2.02M | -$3.02M |
| Capital expenditure | n/a | $1.44M | $2.91M | $0 | $0 |
| Total debt | n/a | $6,764 | $22,265 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | YDES | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.9% | -8.8% | 2nd lowest of 21 |
| 6-month return | +6.6% | -15.3% | 4th highest of 20 |
| Distance from 52-week high | -69.2% | -42.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | +16.9% | +6.8% | 5th highest of 21 |
| Operating margin | -883.3% | 9.4% | lowest of 21 |
| EV / Sales | 571.2× | 4.2× | most expensive of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | 571.2× | n/a | n/a |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 1.4× | -0.3% | -0.7% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 4.2× | 35.3% | +5.2% |
| BioNote 377740.KS | South Korea | $337M | -14% | +12% | 18% | 1.0× | -15.0% | -28.5% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $336M | -36% | -5% | 2% | 4.9× | 34.3% | +0.4% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 5.4× | 18.4% | +4.4% |
| Tauns Laboratories 197A.T | Japan | $327M | -3% | +7% | 29% | 4.4× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $327M | -24% | -10% | 4% | 6.4× | 15.8% | -4.5% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 4.2× | 5.7% | +3.4% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $326M | -34% | -15% | -10% | 6.9× | 20.0% | -5.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $326M | -27% | +12% | -2% | 7.4× | n/a | n/a |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | 3.7× | -13.1% | +36.8% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 1.8× | 19.1% | +0.1% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
| Japan Eyewear 5889.T | Japan | $318M | -5% | +15% | 32% | 3.1× | -9.4% | +20.2% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |